Breast cancer genes: Looking for BRACA’s lost brother

Israel Medical Association Journal

Volumn 16, Issue 12, 2014, Pages 787-792

  Cornejo Moreno, Borys A ^a,b,c   Uribe Escamilla, Diego ^d   Salamanca Gómez, Fabio ^d,e  

^a Clínica y Diagnóstico Genético   (El Salvador)

^b Hospital central Ginecologico   (El Salvador)

^c Escuela de Medicina Intermédica   (Mexico)

^d SECRETARÍA DE SALUD   (Mexico)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

BRCA1; BRCA2; BRCA3; Breast cancer; DNA; Genes; HUGO; Penetrance; TP53

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; PROTEIN P53; RAD51 PROTEIN;

BREAST CANCER; CANCER RISK; COMPARATIVE GENOMIC HYBRIDIZATION; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA REPAIR; GENE LOCUS; GENE MUTATION; HETERODUPLEX ANALYSIS; HUMAN; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE; BREAST NEOPLASMS; FEMALE; GENETIC HETEROGENEITY; GENETICS; GERMLINE MUTATION; MALE; PENETRANCE; PREVALENCE; RISK ASSESSMENT;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, P53; GENETIC HETEROGENEITY; GERM-LINE MUTATION; HUMANS; MALE; PENETRANCE; PREVALENCE; RISK ASSESSMENT;

EID: 84919792926     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Bingham SA, Luben R, Welch A, Wareham N, Khaw KT, Day N. Are imprecise methods obscuring a relation between fat and breast cancer? Lancet 2003; 362 (9379): 212-14.
2. Barnes DR, Antoniou AC. Unraveling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers. J Intern Med 2012; 271: 331-43.
3. Hedenfalk I, Ringner M, Ben-Dor A, et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003; 100 (5): 2532-7.
4. Fodor FH, Weston A, Bleiweiss IJ, et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63 (1): 45-51.
5. McKusick V. Cancer of the breast and female reproductive tract. In: Rimoin D, Connor M, Pyeritz R, eds. Principles and Practice of Medical Genetics. New York: Churchill Livingstone, 1997: 2093-121.
6. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250 (4988): 1684-9.
7. Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1993b; 52 (4): 678-701.
8. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266 (5182): 66-71.
9. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265 (5181): 2088-90.
10. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378 (6559): 789-92.
11. Lee JS, Collins KM, Brown AL, Lee CH, Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 2002; 404 (6774): 201-4.
12. Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000; 16 (2): 69-74.
13. Tutt A, Ashworth A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med 2002; 8 (12): 571-6.
14. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51-62.
15. Shamoo Y. Structural insights into BRCA2 function. Curr Opin Struc Biol 2003; 13 (2): 206-11.
16. Friedman LS, Ostermeyer EA, Szabo CI, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet 1994; 8: 399-404.
17. Xiao W, Oefner P. Denaturing high-performance liquid chromatography: a review. Hum Mutat 2001; 17: 439-74.
18. Willems PJ. Susceptibility genes in breast cancer: more is less? Clin Genet 2007; 72: 493-4.
19. Hodgson SV, Morrison PJ, Irving M. Breast cancer genetics: unsolved questions and open perspectives in an expanding clinical practice. Am J Med Genet 2004; 129 (1): 56-64.
20. Genome Bioinformatics Group at Center for Biomolecular Science and Engineering UCSC genome bioinformatics. Available at http://genome.cse.ucsc.edu/cgi-bin/hgGene?hgg_gene=uc002ico.1&hgg_prot=P38398&hgg_chrom=chr17&hgg_start=38449839&hgg_end=38530657&hgg_type=knownGene&db=hg18&hgsid=100101404. Accessed July 16, 2013.
21. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344 (8): 539-48.
22. Couch FJ, DeShano ML, Blackwood MA, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336 (20): 1409-15.
23. Thompson D, Szabo CI, Mangion J, et al. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci USA 2002; 99 (2): 827-31.
24. Li FP. Familial cancer syndromes and clusters. Curr Prob Cancer 1990; 14 (2): 73-114.
25. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993; 329 (8): 517-23.
26. Lobaccaro JM, Lumbroso S, Belon C, et al. Androgen receptor gene mutation in male breast cancer. Hum Mol Genet 1993; 2 (11): 1799-802.
27. Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V. Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 1994; 54 (17): 4607-9.
28. Shugart YY, Cour C, Renard H, et al. Linkage analysis of 56 multiplex families excludes the Cowden disease gene PTEN as a major contributor to familial breast cancer. J Med Genet 1999; 36 (9): 720-1.
29. Boardman LA, Thibodeau SN, Schaid DJ, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128 (11): 896-9.
30. Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002; 11 (12): 1399-407.
31. de Jong MM, Nolte IM, de Vries EG, et al. The HLA class III subregion is responsible for an increased breast cancer risk. Hum Mol Genet 2003; 12 (18): 2311-19.
32. Karppinen SM, Heikkinen K, Rapakko K, Winqvist R. Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer. J Med Genet 2004; 41 (9): 114.
33. Hopper JL, Hayes VM, Spurdle AB, et al. A protein-truncating mutation in CYP17A1 in three sisters with early-onset breast cancer. Hum Mutat 2005; 26 (4): 298-302.
34. Zhang L, Huang J, Yang N, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA 2006; 103 (24): 9136-41.
35. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39 (2): 165-7.
36. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447 (7148): 1087-93.
37. Evans DG, Howell A. Breast cancer risk-assessment models. Breast Cancer Res 2007; 9: 213.
38. Breast Cancer Risk and Environmental Factors. Available at: http://www.niehs.nih.gov. Accessed March 2013.
39. Sakoda LC, Jorgenson E, Witte JS. Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet 2013; 45 (4): 345-8